Sunshine Biopharma (SBFM) is scheduled to report Q4 earnings on March 31, 2026. Analysts estimate EPS of $-0.27 and quarterly revenue of $10.00M.

In the most recent quarter (Q3), Sunshine Biopharma reported EPS of $-0.19, missing estimates of $-0.12 by 0.58%. Revenue came in at $9.42M, missing the estimate of $12.00M by 0.22%.

Sunshine Biopharma has missed EPS estimates in 3 consecutive quarters.

Over the last 4 quarters, Sunshine Biopharma has averaged an EPS surprise of 0.67% and a revenue surprise of 0.15%.